Acyl modifications in bovine, porcine, and equine ghrelins.

Ghrelin is a peptide hormone with various important physiological functions. The unique feature of ghrelin is its serine 3 acyl-modification, which is essential for ghrelin activity. The major form of ghrelin is modified with n-octanoic acid (C8:0) by ghrelin O-acyltransferase. Various acyl modifications have been reported in different species. However, the underlying mechanism by which ghrelin is modified with various fatty acids remains to be elucidated. Herein, we report the purification of bovine, porcine, and equine ghrelins. The major active form of bovine ghrelin was a 27-amino acid peptide with an n-octanoyl (C8:0) modification at Ser3. The major active form of porcine and equine ghrelin was a 28-amino acid peptide. However, porcine ghrelin was modified with n-octanol (C8:0), whereas equine ghrelin was modified with n-butanol (C4:0) at Ser3. This study indicates the existence of structural divergence in ghrelin and suggests that it is necessary to measure the minor and major forms of ghrelin to fully understand its physiology.

Empyema Caused by Pasteurella multocida in a Patient With Chronic Obstructive Respiratory Disease Taking Inhaled Corticosteroids: A Case Report.

Pasteurella multocida (P. multocida) infection develops in patients with chronic obstructive pulmonary disease (COPD). Inhaled corticosteroids (ICS) are used for the treatment of COPD. Herein, we report a case of empyema caused by P. multocida in a patient using ICS for COPD. A 79-year-old man with COPD presented with general fatigue. He was treated with triple therapy including ICS. Contrast-enhanced computed tomography revealed encapsulated pleural effusion in the left chest. We initiated antibiotics, sulbactam sodium/ampicillin sodium (3 g × 4), and thoracic drainage. His pleural effusion culture turned out positive and P. multocida was detected. The patient was diagnosed with empyema caused by P. multocida. The triple therapy combination, including ICS, was changed to a double therapy combination without ICS. The subsequent progress was relatively good, and on the 49th day of hospitalization, the patient was discharged. The onset of P. multocida infection may be associated with ICS use, which may best be avoided in a patient with COPD who is at risk of P. multocida infection.

Pseudo-Meigs' Syndrome in a Patient With Uterine Fibroids With Massive Pleural Effusion After Starting Gonadotropin-Releasing Hormone Agonist Therapy: A Case Report.

Pseudo-Meigs' syndrome is caused by uterine fibroids, which is often treated using gonadotropin-releasing hormone (GnRH) agonists. Here we report a case of pseudo-Meigs' syndrome that developed with massive pleural effusion after the initiation of GnRH agonist therapy for uterine fibroids. A 48-year-old woman presented with dyspnea. Her medical history included uterine fibroids and GnRH agonist therapy. Contrast-enhanced computed tomography revealed a massive pleural effusion, uterine fibroids, and ascites. A total laparoscopic hysterectomy was performed. The pathologic findings were consistent with those of uterine fibroids. The pleural effusion and ascites resolved completely. The patient was diagnosed with pseudo-Meigs' syndrome due to uterine fibroids.

[Coexistence of Lung Adenocarcinoma and Non-caseous Epithelioid Granuloma Possibly due to Systemic Sarcoidosis in the Same Lesion].

A lung cancer coexists with non-caseous epithelioid granulomas (NEG) in the same lesion is uncommon. A 62-year-old female was referred to our hospital for examination of a right lung S3 nodule which was recently increasing in its size. Positron emission tomography-computed tomography (PET-CT) examination revealed positive signals at the S3 nodule as well as mediastinal lymph nodes, apex of heart and right pleura. Pathological examination revealed the S3 nodule coexisting with both adenocarcinoma and NEG. The differential diagnosis between the systemic sarcoidosis and sarcoid reaction is usually important in such a case. Since the pleura and mediastinal lymph nodes contained many NEGs, the adenocarcinoma arising based on the systemic sarcoidosis was possibly suggested in the present case.

QCD-Electroweak First-Order Phase Transition in a Supercooled Universe.

If the electroweak sector of the standard model is described by classically conformal dynamics, the early Universe evolution can be substantially altered. It is already known that-contrarily to the standard model case-a first-order electroweak phase transition may occur. Here we show that, depending on the model parameters, a dramatically different scenario may happen: A first-order, six massless quark QCD phase transition occurs first, which then triggers the electroweak symmetry breaking. We derive the necessary conditions for this dynamics to occur, using the specific example of the classically conformal B-L model. In particular, relatively light weakly coupled particles are predicted, with implications for collider searches. This scenario is also potentially rich in cosmological consequences, such as renewed possibilities for electroweak baryogenesis, altered dark matter production, and gravitational wave production, as we briefly comment upon.

Controlling the excited state and photosensitizing property of a 2-(2-pyridyl)benzo[b]thiophene-based cationic iridium complex through simple chemical modification.

Bis-cyclometalated cationic iridium (Ir) complexes 1-4 comprising two 2-(2-pyridyl)benzo[b]thiophene (btp) ligands and one 2,2'-bipyridyl (bpy) ancillary ligand with different substituents were prepared as new visible light-absorbing sensitizers and examined for their photophysical and electrochemical properties. Complex 1 was prepared as a parent complex without any substituents. Complexes 2-4 contained methyl-, methoxy-, and trifluoromethyl groups at 4,4'-positions on the bpy ancillary ligand. Systematic investigation of these complexes revealed that such a simple chemical modification selectively controls the excited-state lifetime, while the absorption and emission spectral features remain unchanged. Specifically, the phosphorescence lifetimes of complexes 2 and 3 with electron-donating groups (τ = 3.50 µs, 3.90 µs) were found to be much longer than that of complex 1 (τ = 0.273 µs), and complex 4, possessing strong electron-withdrawing trifluoromethyl groups, did not exhibit detectable phosphorescence at room temperature. The large differences in excited-state lifetimes of complexes 1-3, as well as the nonemissive character of complex 4, are attributed to a strong influence of the substituents on the ligand field strength. The increased σ-donating ability of the ancillary ligand in complexes 2 and 3 destabilizes a short-lived, nonemissive triplet metal-centered ((3)MC) state and increases the energy separation between the (3)MC state and emissive triplet ligand-centered ((3)LC) state based on the btp ligand. For complex 4, however, the (3)MC state is close in energy to the (3)LC state because of the decreased σ-donating ability of the ancillary ligand. Additional evidence of the (3)MC state associated with the changeable excited state was also provided via low-temperature phosphorescence measurements and density functional theory calculations. Ir complexes 1-4 were tested as sensitizers in photoinduced electron-transfer reaction of triethanolamine and methylviologen chloride (MVCl2). As a result, complexes 2 and 3 exhibited much better photosensitizing property compared to complex 1 since their long-lived excited states promoted an oxidative quenching pathway. This Study has first demonstrated that simple substitution on the diimine ancillary ligand can control the (3)MC state of the bis-cyclometalated cationic Ir complex to finely tune the excited-state lifetime and photosensitizing property.